SCM
AMLX icon

Sterling Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Sterling Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.8K Sell
323
-814
-72% -$12.6K ﹤0.01% 2530
2026
Q1 		$15.8K Sell
1,137
-490
-30% -$6.89K ﹤0.01% 2130
2025
Q4 		$19.7K Buy
1,627
+418
+35% +$5.68K ﹤0.01% 2238
2025
Q3 		$16.4K Buy
1,209
+657
+119% +$6.18K ﹤0.01% 2238
2025
Q2 		$3.54K Buy
+552
New +$2.69K ﹤0.01% 2701

Other funds holding AMLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
IGAM
iA Global Asset Management Quebec, Quebec, Canada $8.42B AUM 47.61% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return

Sterling Capital Management's AMLX Position: Q2 2026 in Review

Sterling Capital Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 72% in Q2 2026, selling an estimated $12.6K and leaving 323 shares worth $5.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2530.

Sterling Capital Management first reported a position in AMLX in Q2 2025 and has held it in 5 quarters since. The position peaked at $19.7K in Q4 2025. 59 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Sterling Capital Management held 323 shares of Amylyx Pharmaceuticals worth $5.8K as of Q2 2026.
  • Sterling Capital Management sold 814 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $12.6K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2530 holding.
  • Sterling Capital Management first reported a position in Amylyx Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Sterling Capital Management's Amylyx Pharmaceuticals position peaked at $19.7K in Q4 2025.
  • 59 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.